Basit öğe kaydını göster

dc.contributor.authorÖkten, Sabri Berkem
dc.contributor.authorÇetin, Çağlar
dc.contributor.authorTok, Olgu Enis
dc.contributor.authorGüler, Eray Metin
dc.contributor.authorTaha, Sevde Havva
dc.contributor.authorÖzcan, Pınar
dc.contributor.authorFıçıcıoğlu, Cem
dc.date.accessioned2023-06-01T07:44:10Z
dc.date.available2023-06-01T07:44:10Z
dc.date.issued2023en_US
dc.identifier.citationÖkten, S. B., Çetin, Ç., Tok, O. E., Güler, E. M., Taha, S. H., Özcan, P. ... Fıçıcıoğlu, C. (2023). Cannabidiol as a potential novel treatment for endometriosis by its anti-inflammatory, antioxidative and antiangiogenic effects in an experimental rat model. Reproductive BioMedicine Online, 46(5), 865-875. https://doi.org/10.1016/j.rbmo.2023.01.018en_US
dc.identifier.issn1472-6483
dc.identifier.issn1472-6491
dc.identifier.urihttps://doi.org/10.1016/j.rbmo.2023.01.018
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11007
dc.description.abstractResearch question: Can cannabidiol (CBD) be used in the treatment of endometriosis for its anti-inflammatory, antioxidative and antiangiogenic effects? Design: Endometrial implants were surgically induced in 36 female Wistar albino rats. After confirmation of endometriotic foci, the rats were randomized into four groups. In the leuprolide acetate group, rats were given a single 1 mg/kg s.c. leuprolide acetate injection. The other groups were 5 mg/kg CBD (CBD5), saline solution and 20 mg/kg CBD (CBD20); daily i.p. injections were administered for 7 days. After 21 days, the rats were euthanised, and total antioxidant status (TAS), total oxidant status (TOS), oxidative stress index (OSI), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-a) measurements in blood and peritoneal fluid samples, and immunohistochemical staining for TNF-a, IL-6 and vascular endothelial growth factor (VEGF) of endometriotic tissues were evaluated. Results: Significant reductions in the endometriotic implant surface area (P = 0.0213), serum TOS (P = 0.0491), OSI (P = 0.0056), IL-6 (P = 0.0236), TNF-a (P = 0.0083) and peritoneal fluid OSI (P = 0.0401), IL-6 (P = 0.0205) and TNF-a (P = 0.0045) concentrations were observed in the CBD5 group when compared with the saline solution group. Compared with the saline solution group, increased TAS concentrations in serum (P = 0.0012) and peritoneal fluid (P = 0.0145) were found in the CBD5 group. The CBD5 and leuprolide acetate groups were similar regarding inflammatory and oxidative stress parameters of serum and peritoneal fluid samples. The CBD5 group showed significantly lower mean intensity in both surface epithelium and stromal cells for VEGF (both P = 0.002) and only in surface epithelium cells for IL-6 (P = 0.0108), when compared with the leuprolide acetate group. Conclusion: Due to its anti-inflammatory, antioxidative and antiangiogenic effects, CBD might be a therapeutic agent candidate for endometriosis.en_US
dc.description.sponsorshipDepartment of Biostatistics ; Reakiro Company ; Bezmialem Vakif Universityen_US
dc.language.isoengen_US
dc.publisherElsevier Science Ltden_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectAngiogenesisen_US
dc.subjectCannabidiolen_US
dc.subjectEndometriosis Treatmenten_US
dc.subjectInflammationen_US
dc.subjectOxidative Stressen_US
dc.subjectPhytocannabinoidsen_US
dc.titleCannabidiol as a potential novel treatment for endometriosis by its anti-inflammatory, antioxidative and antiangiogenic effects in an experimental rat modelen_US
dc.typearticleen_US
dc.relation.ispartofReproductive BioMedicine Onlineen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Histoloji ve Embriyoloji Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsüen_US
dc.authorid0000-0002-4899-9146en_US
dc.identifier.volume46en_US
dc.identifier.issue5en_US
dc.identifier.startpage865en_US
dc.identifier.endpage875en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.rbmo.2023.01.018en_US
dc.institutionauthorTok, Olgu Enis
dc.identifier.wosqualityQ1en_US
dc.identifier.wos000992305600001en_US
dc.identifier.scopus2-s2.0-85151274360en_US
dc.identifier.pmid36997400en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster